W J Zhu1, J Wang2, X H He2, Y Qin2, S Yang2, X S Hu2, H Y Wang2, J Huang2, A P Zhou2, F Ma2, Y K Shi2, S Y Zhou2. 1. Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. 2. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract
Objective: To investigate the principles of differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of novel coronavirus (2019-nCoV) by analyzing one case of lymphoma who presented pulmonary ground-glass opacities (GGO) after courses of chemotherapy. Methods: Baseline demographics and clinicopathological data of eligible patients were retrieved from medical records. Information of clinical manifestations, history of epidemiology, lab tests and chest CT scan images of visiting patients from February 13 to February 28 were collected. Literatures about pulmonary infiltrates in cancer patients were searched from databases including PUBMED, EMBASE and CNKI. Results: Among the 139 cancer patients who underwent chest CT scans before chemotherapy, pulmonary infiltrates were identified in eight patients (5.8%), five of whom were characterized with GGOs in lungs. 2019-nCoV nuclear acid testing was performed in three patients and the results were negative. One case was a 66-year-old man who was diagnosed with non-Hodgkin lymphoma and underwent CHOP chemotherapy regimen. His chest CT scan image displayed multiple GGOs in lungs and the complete blood count showed decreased lymphocytes. This patient denied any contact with confirmed/suspected cases of 2019-nCoV infection, fever or other respiratory symptoms. Considering the negative result of nuclear acid testing, this patient was presumptively diagnosed with viral pneumonia and an experiential anti-infection treatment had been prescribed for him. Conclusions: The 2019 novel coronavirus disease (COVID-19) complicates the clinical scenario of pulmonary infiltrates in cancer patients. The epidemic history, clinical manifestation, CT scan image and lab test should be taken into combined consideration. The 2019-nCoV nuclear acid testing might be applied in more selected patients. Active anti-infection treatment and surveillance of patient condition should be initiated if infectious disease is considered.
Objective: To investigate the principles of differential diagnosis of pulmonary infiltrates in cancerpatients during the outbreak of novel coronavirus (2019-nCoV) by analyzing one case of lymphoma who presented pulmonary ground-glass opacities (GGO) after courses of chemotherapy. Methods: Baseline demographics and clinicopathological data of eligible patients were retrieved from medical records. Information of clinical manifestations, history of epidemiology, lab tests and chest CT scan images of visiting patients from February 13 to February 28 were collected. Literatures about pulmonary infiltrates in cancerpatients were searched from databases including PUBMED, EMBASE and CNKI. Results: Among the 139 cancerpatients who underwent chest CT scans before chemotherapy, pulmonary infiltrates were identified in eight patients (5.8%), five of whom were characterized with GGOs in lungs. 2019-nCoV nuclear acid testing was performed in three patients and the results were negative. One case was a 66-year-old man who was diagnosed with non-Hodgkin lymphoma and underwent CHOP chemotherapy regimen. His chest CT scan image displayed multiple GGOs in lungs and the complete blood count showed decreased lymphocytes. This patient denied any contact with confirmed/suspected cases of 2019-nCoV infection, fever or other respiratory symptoms. Considering the negative result of nuclear acid testing, this patient was presumptively diagnosed with viral pneumonia and an experiential anti-infection treatment had been prescribed for him. Conclusions: The 2019 novel coronavirus disease (COVID-19) complicates the clinical scenario of pulmonary infiltrates in cancerpatients. The epidemic history, clinical manifestation, CT scan image and lab test should be taken into combined consideration. The 2019-nCoV nuclear acid testing might be applied in more selected patients. Active anti-infection treatment and surveillance of patient condition should be initiated if infectious disease is considered.
Authors: Beth Russell; Charlotte Moss; Gincy George; Aida Santaolalla; Andrew Cope; Sophie Papa; Mieke Van Hemelrijck Journal: Ecancermedicalscience Date: 2020-03-27
Authors: Oscar Arrieta; Andrés F Cardona; Luis Lara-Mejía; David Heredia; Feliciano Barrón; Zyanya Lucia Zatarain-Barrón; Francisco Lozano; Vladmir Cordeiro de Lima; Federico Maldonado; Francisco Corona-Cruz; Maritza Ramos; Luis Cabrera; Claudio Martin; Luis Corrales; Mauricio Cuello; Marisol Arroyo-Hernández; Enrique Aman; Ludwing Bacon; Renata Baez; Sergio Benitez; Antonio Botero; Mauricio Burotto; Christian Caglevic; Gustavo Ferraris; Helano Freitas; Diego Lucas Kaen; Sebastián Lamot; Gustavo Lyons; Luis Mas; Andrea Mata; Clarissa Mathias; Alvaro Muñoz; Ana Karina Patane; George Oblitas; Luis Pino; Luis E Raez; Jordi Remon; Leonardo Rojas; Christian Rolfo; Alejandro Ruiz-Patiño; Suraj Samtani; Lucia Viola; Santiago Viteri; Rafael Rosell Journal: Crit Rev Oncol Hematol Date: 2020-06-20 Impact factor: 6.312
Authors: Cristina Gamila Wakfie-Corieh; Federico Ferrando-Castagnetto; Alba María Blanes García; Marta García García-Esquinas; Aída Ortega Candil; Cristina Rodríguez Rey; María Nieves Cabrera-Martín; Ana Delgado Cano; José Luis Carreras Delgado Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057